Table 1.
Characteristics of the cases
| Characteristics of the cases | n = 379 |
|---|---|
| Neonatal sex: females, n (%) | 139 (36.7%) |
| Neonatal age (days), median (Q1–Q3) | 1.0 (0.0–2.0) |
| Country | |
| Europe | 261 (68.9%) |
| North America | 75 (19.8%) |
| Asia | 33 (8.7%) |
| Oceania | 9 (2.4%) |
| Other | 1 (0.3%) |
| Maternal dose (DDD), median (Q1–Q3) | 1.00 (0.7–2.0) |
| Maternal duration of treatment (weeks), median (Q1–Q3) | 36.71 (28.0–39.0) |
| Duration of the neonatal withdrawal symptoms (days), median (Q1–Q3) | 7.0 (3.0–11.0) |
| Serious reaction (n, %)a | 318 (83.9%) |
| With at least one reported psychotropic maternal co-medication, n (%) | 209 (55.1%) |
| With mood stabilizers (n) | 36 (9.5%) |
| With benzodiazepines (n) | 114 (30.1%) |
| With other antidepressants (n) | 45 (11.9%) |
| With antipsychotics (n) | 88 (23.2%) |
| With opioids (n) | 51 (13.5) |
DDD, defined daily dose; n, number of neonates; Q1, first quartile; Q3, third quartile.
a
Data on symptom severity were available for 330 patients.